NCT05417386 - FOLFIRINOX + NIS793 in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions

Pancreas CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma

Interventions

DRUG

FOLFIRINOX

Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion

DRUG

Oxaliplatin

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

Leucovorin

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

Irinotecan

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

5-Fluorouracil (5-FU)

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

NIS793

Given by intravenous infusion

RADIATION

Chemoradiation

Combination of Chemo (Capecitabine) and Radiation Therapy

DRUG

Capecitabine

Taken Orally as part of Chemoradiation

RADIATION

Radiation Therapy

Radiation Therapy as part of Chemoradiation

PROCEDURE

Surgery

Surgical removal of tumor

Trial Locations (1)

Massachusetts General Hospital Cancer Center, Boston